DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR NEXAVAR
Clinical Trials for Nexavar
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00064350 | Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different human tumor types including colon, pancreatic, lung, and ovarian. This activity was cytostatic in nature and was maintained if dosing was continued. That is, tumor growth is suspended while the drug is administered but returns to baseline rates when the agent is withdrawn. Therefore, the optimal schedule will be an uninterrupted one. To assess the activity of sorafenib in a timely manner and with a meaningful interpretation, a randomized discontinuation design was adopted in the present trial, conducted in a population who were potentially sensitive to sorafenib. PURPOSE: This randomized phase II trial is studying sorafenib to see how well it works compared to placebo in treating patients with refractory non-small cell lung cancer. |
NCT00064350 | Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer | Completed | Eastern Cooperative Oncology Group | Phase 2 | RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different human tumor types including colon, pancreatic, lung, and ovarian. This activity was cytostatic in nature and was maintained if dosing was continued. That is, tumor growth is suspended while the drug is administered but returns to baseline rates when the agent is withdrawn. Therefore, the optimal schedule will be an uninterrupted one. To assess the activity of sorafenib in a timely manner and with a meaningful interpretation, a randomized discontinuation design was adopted in the present trial, conducted in a population who were potentially sensitive to sorafenib. PURPOSE: This randomized phase II trial is studying sorafenib to see how well it works compared to placebo in treating patients with refractory non-small cell lung cancer. |
NCT00079612 | Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer | Completed | Onyx Pharmaceuticals | Phase 2 | The purpose of the study is to: - Find out if BAY 43-9006 prevents the growth of tumors - For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time. - Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY 43-9006 (sorafenib) in the treatment of advanced refractory cancers. - Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients. |
NCT00079612 | Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer | Completed | Bayer | Phase 2 | The purpose of the study is to: - Find out if BAY 43-9006 prevents the growth of tumors - For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time. - Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY 43-9006 (sorafenib) in the treatment of advanced refractory cancers. - Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients. |
Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Nexavar
Condition Name
Condition MeSH
Clinical Trial Locations for Nexavar
Trials by Country
Clinical Trial Progress for Nexavar
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Nexavar
Sponsor Name